Pathological and oncological outcomes of off-criteria radical prostatectomy in patients opting for active surveillance: From PRIAS-JAPAN.
Authors:
- Yoichiro TohiYTYoichiro Tohi
- Takuma KatoTKTakuma Kato
- Masaki NakamuraMNMasaki Nakamura
- Ryuji MatsumotoRMRyuji Matsumoto
- Hiroshi SasakiHSHiroshi Sasaki
- Koji MitsuzukaKMKoji Mitsuzuka
- Junichi InokuchiJIJunichi Inokuchi
- Katsuyoshi HashineKHKatsuyoshi Hashine
- Akira YokomizoAYAkira Yokomizo
- Hidefumi KinoshitaHKHidefumi Kinoshita
- Isao HaraIHIsao Hara
- 20 February 2022
- journal article
- conference paper
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (6_suppl) , 250
Abstract
250 Background: Trigger for definitive treatment in active surveillance (AS) is strictly criteria-based, but some patients might be surgically treated without adherence to the criteria. We aimed to evaluate whether oncological outcomes differ depending on adherence to the criteria in patients who opting for AS. Methods: We retrospectively reviewed data of 1,035 patients enrolled in a prospective cohort of PRIAS-JAPAN. Of 162 patients underwent radical prostatectomy, 136 patients were analyzed, excluding those with Gleason score 3+4 at diagnosis, RP within one year of enrollment. Triggers for RP due to pathological reclassification on repeat biopsy was defined as on-criteria. We compared pathological findings on RP and prostate specific antigen (PSA) recurrence-free survival of on-criteria with off-criteria. Results: Off-criteria was 35 patients (24.7%). There were significant differences in the median time to RP (16 vs. 18.5 months, p0.999) were not significantly different. At a median postoperative follow-up of 36 months, no significant difference in PSA recurrence-free survival was found (log-rank p = 0.828). Conclusions: Although half of off-criteria patients underwent RP within 3 years of starting AS, their oncological outcomes were not different from on-criteria. Our result suggested the potential for tailoring the inclusion criteria of AS within the strict protocol. Clinical trial information: 000002874.Keywords
Funding Information
- None.